Health News

Cancer Research UK’s Drug Development Office has launched a clinical trial* to test an experimental drug in patients with advanced (Stage IV) pancreatic cancer - one of the most difficult cancers to treat.

Read more

Filed under: Pharmacy News
Tags: cancer, Drug, Pharmacy

Related posts

• Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine (0)
  Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has requested Scientific Advice from the European Medicines Agency (EMA) to assure the acceptability of the recently initiated Phase 3 programs for the development of its lead anticancer compound, perifosine, in its two lead indications, multiple myeloma [...]
  
  
• Æterna Zentaris commences perifosine Phase 3 registration trial (0)
  Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced the initiation of a Phase 3 registration clinical trial with perifosine (KRX-0401) ), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer. Read [...]
  
  
• Zoledronic acid may extend survival in older breast cancer patients (0)
  A drug used to protect bone may extend survival in older breast cancer patients, according to researchers at the Universities of Sheffield and Leeds. Read more [tags] Pharmacy News [/tags]
  
  
• ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer (0)
  ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate. Read more [tags] Pharmacy News [/tags]
  
  
• ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma model (0)
  ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide in a pediatric sarcoma model. Read more [tags] Pharmacy News [/tags]